Literature DB >> 33716675

Inflammation Spreading: Negative Spiral Linking Systemic Inflammatory Disorders and Alzheimer's Disease.

Junjun Ni1, Zhou Wu2,3.   

Abstract

As a physiological response to injury in the internal body organs, inflammation is responsible for removing dangerous stimuli and initiating healing. However, persistent and exaggerative chronic inflammation causes undesirable negative effects in the organs. Inflammation occurring in the brain and spinal cord is known as neuroinflammation, with microglia acting as the central cellular player. There is increasing evidence suggesting that chronic neuroinflammation is the most relevant pathological feature of Alzheimer's disease (AD), regulating other pathological features, such as the accumulation of amyloid-β (Aβ) and hyperphosphorylation of Tau. Systemic inflammatory signals caused by systemic disorders are known to strongly influence neuroinflammation as a consequence of microglial activation, inflammatory mediator production, and the recruitment of peripheral immune cells to the brain, resulting in neuronal dysfunction. However, the neuroinflammation-accelerated neuronal dysfunction in AD also influences the functions of peripheral organs. In the present review, we highlight the link between systemic inflammatory disorders and AD, with inflammation serving as the common explosion. We discuss the molecular mechanisms that govern the crosstalk between systemic inflammation and neuroinflammation. In our view, inflammation spreading indicates a negative spiral between systemic diseases and AD. Therefore, "dampening inflammation" through the inhibition of cathepsin (Cat)B or CatS may be a novel therapeutic approach for delaying the onset of and enacting early intervention for AD.
Copyright © 2021 Ni and Wu.

Entities:  

Keywords:  Alzheimer’s disease; cathepsin; cytokines; macrophages; neuroinflammation; systemic inflammation; systemic inflammatory disorders

Year:  2021        PMID: 33716675      PMCID: PMC7947253          DOI: 10.3389/fncel.2021.638686

Source DB:  PubMed          Journal:  Front Cell Neurosci        ISSN: 1662-5102            Impact factor:   5.505


  140 in total

1.  Anti-inflammatory drugs and Alzheimer disease.

Authors:  P L McGeer; E McGeer; J Rogers; J Sibley
Journal:  Lancet       Date:  1990-04-28       Impact factor: 79.321

2.  Leptomeningeal cells activate microglia and astrocytes to induce IL-10 production by releasing pro-inflammatory cytokines during systemic inflammation.

Authors:  Zhou Wu; Jian Zhang; Hiroshi Nakanishi
Journal:  J Neuroimmunol       Date:  2005-10       Impact factor: 3.478

3.  Glutamate release in the nucleus tractus solitarius induced by peripheral lipopolysaccharide and interleukin-1 beta.

Authors:  P Mascarucci; C Perego; S Terrazzino; M G De Simoni
Journal:  Neuroscience       Date:  1998-10       Impact factor: 3.590

Review 4.  Inflammation and dementia: Using rheumatoid arthritis as a model to develop treatments?

Authors:  Alice Mason; Clive Holmes; Christopher J Edwards
Journal:  Autoimmun Rev       Date:  2018-07-10       Impact factor: 9.754

5.  Inhibitors of cathepsin B improve memory and reduce beta-amyloid in transgenic Alzheimer disease mice expressing the wild-type, but not the Swedish mutant, beta-secretase site of the amyloid precursor protein.

Authors:  Vivian Y H Hook; Mark Kindy; Gregory Hook
Journal:  J Biol Chem       Date:  2008-01-09       Impact factor: 5.157

6.  Lipopolysaccharide impairs amyloid β efflux from brain: altered vascular sequestration, cerebrospinal fluid reabsorption, peripheral clearance and transporter function at the blood-brain barrier.

Authors:  Michelle A Erickson; Pehr E Hartvigson; Yoichi Morofuji; Joshua B Owen; D Allan Butterfield; William A Banks
Journal:  J Neuroinflammation       Date:  2012-06-29       Impact factor: 8.322

7.  Different Brain Regions are Infected with Fungi in Alzheimer's Disease.

Authors:  Diana Pisa; Ruth Alonso; Alberto Rábano; Izaskun Rodal; Luis Carrasco
Journal:  Sci Rep       Date:  2015-10-15       Impact factor: 4.379

8.  Gut microbiome alterations in Alzheimer's disease.

Authors:  Nicholas M Vogt; Robert L Kerby; Kimberly A Dill-McFarland; Sandra J Harding; Andrew P Merluzzi; Sterling C Johnson; Cynthia M Carlsson; Sanjay Asthana; Henrik Zetterberg; Kaj Blennow; Barbara B Bendlin; Federico E Rey
Journal:  Sci Rep       Date:  2017-10-19       Impact factor: 4.379

9.  Porphyromonas gingivalis in Alzheimer's disease brains: Evidence for disease causation and treatment with small-molecule inhibitors.

Authors:  Stephen S Dominy; Casey Lynch; Florian Ermini; Malgorzata Benedyk; Agata Marczyk; Andrei Konradi; Mai Nguyen; Ursula Haditsch; Debasish Raha; Christina Griffin; Leslie J Holsinger; Shirin Arastu-Kapur; Samer Kaba; Alexander Lee; Mark I Ryder; Barbara Potempa; Piotr Mydel; Annelie Hellvard; Karina Adamowicz; Hatice Hasturk; Glenn D Walker; Eric C Reynolds; Richard L M Faull; Maurice A Curtis; Mike Dragunow; Jan Potempa
Journal:  Sci Adv       Date:  2019-01-23       Impact factor: 14.136

10.  Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression.

Authors:  Xinyi Wang; Guangqiang Sun; Teng Feng; Jing Zhang; Xun Huang; Tao Wang; Zuoquan Xie; Xingkun Chu; Jun Yang; Huan Wang; Shuaishuai Chang; Yanxue Gong; Lingfei Ruan; Guanqun Zhang; Siyuan Yan; Wen Lian; Chen Du; Dabing Yang; Qingli Zhang; Feifei Lin; Jia Liu; Haiyan Zhang; Changrong Ge; Shifu Xiao; Jian Ding; Meiyu Geng
Journal:  Cell Res       Date:  2019-09-06       Impact factor: 25.617

View more
  1 in total

1.  Review of evidence implicating the plasminogen activator system in blood-brain barrier dysfunction associated with Alzheimer's disease.

Authors:  Mei-Yun Tang; Fredric A Gorin; Pamela J Lein
Journal:  Ageing Neurodegener Dis       Date:  2022-01-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.